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Incident Heart Failure in Patients With Rheumatoid Arthritis:
A Nationwide Cohort Study
Usman Khalid, MD, PhD; Alexander Egeberg, MD, PhD; Ole Ahlehoff, MD, PhD; Deirdre Lane, MD, PhD, DMSc; Gunnar H. Gislason, MD,
PhD; Gregory Y.H. Lip, MD, PhD, DMSc;* Peter R. Hansen, MD, PhD, DMSc*
Background-—Rheumatoid arthritis (RA) is a chronic inﬂammatory disease associated with a wide range of comorbidities, including
cardiovascular disease, but its association with heart failure (HF) is not fully clear. We investigated the risk of incident HF in a
nationwide cohort of patients with RA.
Methods and Results-—The study comprised the entire Danish population aged ≥18 years followed from January 1, 2008 until ﬁrst
hospitalization for HF, emigration, December 31, 2012, or death. Information on comorbidity, medication, and socioeconomic
status was identiﬁed by individual-level linkage of administrative registers. Patients with a rheumatologist diagnosis of RA between
1978 and 2008 were included. The primary study outcome was incident HF deﬁned as ﬁrst hospital admission for HF. Incidence
rates of HF per 1000 person-years were calculated and incidence rate ratios adjusted for age, sex, calendar year, comorbidity,
medications, socioeconomic status, smoking, and alcohol consumption were estimated. A total of 4 305 225 subjects with no
history of HF were eligible for analysis at the study start. Of these subjects, 24 343 developed RA and 50 623 were hospitalized
for HF. Overall incidence rates of incident HF were 2.43 and 6.64 for the reference population (n=49 879) and patients with RA
(n=744), respectively. Correspondingly, the fully adjusted incidence rate ratio for incident HF was increased in patients with RA
with incidence rate ratio 1.30 (95% conﬁdence interval, 1.17–1.45).
Conclusions-—In this cohort study, RA was associated with an increased hospitalization for HF. These ﬁndings add signiﬁcantly to
the existing evidence of RA as a clinically relevant risk factor for HF. ( J Am Heart Assoc. 2018;7:e007227. DOI: 10.1161/JAHA.
117.007227.)
Key Words: cardiovascular disease • heart failure • inﬂammation • rheumatoid arthritis
P atients with rheumatoid arthritis (RA) and other chronicinﬂammatory disorders (eg, psoriasis and inﬂammatory
bowel disease) suffer considerably increased cardiovascular
morbidity and mortality when compared with the background
population.1–5 In patients with RA, the excess cardiovascular
disease risk appears to be comparable with that found in
patients with type 2 diabetes mellitus.6,7 Both conventional
cardiovascular risk factors (eg, hypertension, obesity, dyslipi-
demia, and diabetes mellitus) and increased systemic inﬂam-
mation play a contributory role.4,8,9
Heart failure (HF) is a growing major public health problem
that is also associated with increased inﬂammation and a high
prevalence of cardiovascular risk factors.10–12 The proinﬂam-
matory cytokines involved in HF promote myocardial damage
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and other pathogenic manifestations through an array of
mechanisms, including, for example, increased arterial stiff-
ness and endothelial dysfunction.13–19
Few studies have examined the risk of developing HF
in patients with RA independent of cardiovascular risk
factors.13,17,20,21 The present study therefore aimed to
investigate the risk of incident HF in a nationwide cohort of
patients with RA by using Danish national administrative and
healthcare registers.
Methods
Setting and Data Sources
Denmark maintains nationwide administrative and health-
care registers that offer a unique possibility for conducting
large-scale epidemiological studies of several end points
with a minimum loss to follow-up.22–25 The Danish Civil
Registration System established in 1968 allocates a perma-
nent and unique civil registration number to each citizen at
birth that allows unambiguous cross-linkage of data across
nationwide registers.24 In the present study, information on
all pharmacy-dispensed prescriptions classiﬁed according to
the Anatomical Therapeutical Chemical classiﬁcation system
was obtained from the Danish Registry for Medical Products
Statistics.22,26 This register was established in 1994 and
records information on dispensing date, strength of the
drug, and the allocated quantity.22 Information on morbidity
was retrieved from the Danish National Patient Register,
which contains data on all inpatient hospital visits and
diagnoses since 1978, and outpatient data since 1995
recorded according to the International Classiﬁcation of
Diseases (ICD) code.23 Hospital-based pharmacological treat-
ment (eg, biological therapy) is also coded in the Danish
National Patient Register as treatment procedure (Sund-
hedvæsenets Klassiﬁkations System) codes.23 This coding of
biological drug treatment has been validated previously.27
Information on age, sex, vital status, and tax-reported
household income was obtained from the Central Population
Register and Statistics Denmark.28 The guidelines for cohort
studies as deﬁned in the Strengthening the Reporting of
Observational Studies in Epidemiology (STROBE) recommen-
dations were applied to the present study.29
Data availability
The data, analytical methods, and study materials cannot be
made available to other researchers for purposes of repro-
ducing the results or replicating the procedure.
Study Subjects
The study cohort comprised all Danes aged ≥18 years alive
and resident in the source population on January 1, 2008 (the
study start date). These individuals were then followed until
the occurrence of the study end point, migration, death, or
December 31, 2012, whichever came ﬁrst. Patients with a
diagnosis of HF (n=56 644) at baseline were excluded from
the study cohort before the study start. Patients diagnosed
with RA (ICD code M5–M6) between 1978 (when the Danish
National Patient Register was established) and 2008 were
identiﬁed (n=24 343). To ensure diagnostic accuracy, we only
included diagnoses of RA made by rheumatologists. The
primary outcome of interest was incident HF, deﬁned as the
ﬁrst hospital admission for HF as primary or secondary
discharge diagnoses (ICD-10 Revision codes I42, I50, I110,
and J819).
Pharmacotherapy and Comorbidity
Baseline pharmacotherapy was deﬁned by dispensed pre-
scriptions up to 6 months preceding study inclusion date with
the following medications: acetylsalicylic acid, cholesterol-
lowering drugs, vitamin K antagonists, digoxin, glucocorti-
coids, and nonsteroidal anti-inﬂammatory drugs. The following
comorbidity was established: atrial ﬁbrillation, diabetes mel-
litus, hypertension, chronic obstructive pulmonary disease,
arterial vascular disease, and thromboembolism. Hyperten-
sion was identiﬁed by either a hospital diagnosis for
hypertension, or concurrent use of at least 2 of the following
classes of antihypertensive agents within a 3-month period:
a-adrenergic blockers, nonloop diuretics, vasodilators,
b-blockers, calcium-channel blockers, and renin-angiotensin
system inhibitors, as previously validated.30 Diabetes mellitus
was deﬁned by either hospital diagnoses, or use of glucose-
lowering agents.31 Smoking history and alcohol consumption
was deﬁned by use of pharmacotherapy, therapeutic inter-
ventions, or diagnoses related to smoking or alcohol abuse,
respectively (see Table S1 for codes).27,32 The respective ICD,
Anatomical Therapeutical Chemical, and Sundhedvæsenets
Clinical Perspective
What Is New?
• In this nationwide study, rheumatoid arthritis was associ-
ated with a 30% increased hospitalization for heart failure
compared with the background population.
What Are the Clinical Implications?
• The ﬁndings add to the existing evidence that rheumatoid
arthritis may be a clinically relevant risk factor for heart
failure.
• Studies examining the value of more-extensive screening of
these patients for heart failure are warranted.
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Klassiﬁkations System codes for all examined comorbidities
and concomitant medications are presented in Table 1.
Statistical Analysis
SAS statistical software (version 9.4; SAS Institute Inc,
Cary, NC) and STATA software (version 14; StataCorp LP,
College Station, TX) were used to perform the statistical
analyses.
Baseline characteristics for cohort participants were
presented as frequencies and percentages for categorical
variables and as means with SDs for continuous variables.
Differences between parameter estimates within the models
were analyzed using unpaired t tests and v2 tests, as
appropriate. Age, follow-up time, and calendar year (divided
into bands of 1-year periods) were included as time scales.
Incidence rates of new events per 1000 person-years were
reported. Multivariable Poisson regression models adjusted
for age, sex, calendar year, comorbidity, concomitant
medications, socioeconomic status, alcohol consumption,
and smoking history were ﬁtted to estimate incidence rate
ratios (IRRs). For all analyses, a 2-tailed P value <0.05 was
considered statistically signiﬁcant, and 95% conﬁdence inter-
vals (CIs) were provided. Model assumptions, including
absence of interaction between covariates, were tested and
found to be valid for all covariates.
Sensitivity Analyses
The diagnosis of HF in the Danish National Registers has
been shown to be under-reported with a sensitivity of 30% to
50% but a speciﬁcity of 99%.33 To increase the sensitivity of
the HF end point, we carried out an analysis where we
changed the deﬁnition of HF to either a prescription of loop
diuretics or a HF diagnosis. Also, to assess the impact of an
HF secondary diagnosis, we performed a sensitivity analysis
where only a primary diagnosis of HF was considered as an
outcome.
Tumor necrosis factor (TNF) alpha inhibitors are frequently
used to treat RA, often alongside disease-modifying antirheu-
matic drugs.34 A few studies have suggested that treatment
with TNF inhibitors may promote HF.35,36 However, more-
recent studies have reported a preventive effect of TNF
inhibitors on overall cardiovascular risk and no signiﬁcant
impact on the risk of HF.37,38 In the present study, we
conducted a further sensitivity analysis where we included
treatment with TNF inhibitors (inﬂiximab, etanercept, and
adalimumab [see Table 1 for Anatomical Therapeutical Chem-
ical/Sundhedvæsenets Klassiﬁkations System codes]) in
multivariable regression models to estimate the impact of
these agents on our primary ﬁndings.
RA is a chronic disease, and, consequently, there is a
marked delay from onset of symptoms to ﬁrst (in-patient or
out-patient) consultation and diagnosis.39 Moreover, studies
have shown that patients with RA with longer disease duration
have a higher risk of cardiovascular adverse events compared
with those with shorter disease duration.40 Thus, an inception
study design, where subjects with prevalent RA are excluded
at baseline, may underestimate the true RA-related effect. For
the present study, we therefore selected a prevalent study
design to better represent patients with RA in the general
population. However, in order to assess the risk of HF in
patients with new-onset RA, we also conducted a sensitivity
analysis comprising all Danish citizens aged ≥18 years
included on January 1, 2002, without a history of RA and
HF. These subjects were followed until the occurrence of HF,
migration, death, or December 31, 2012. To ensure an
accurate allocation of exposure time, we used a time-
dependent approach that allowed subjects who developed
RA during the study time to contribute with time at risk in the
reference group until the RA index date.
Table 1. Overview of ICD, ATC, and SKS Codes
Comorbidity ICD-10/ICD-8
Arterial vascular disease I21 to I22, I70, 410, and 440
Atrial fibrillation I48 and 4279
Diabetes mellitus E10 to E14 and 250
Thromboembolism I26, I63, I64, I74, G458, G459,
433 to 438, 444, and 450
Hypertension I10 to I15 and 400 to 404
Renal disease N03, N04, N17 to N19, R34, I12,
I13, and 582 to 588
Chronic obstructive
pulmonary disease
J42, J44, and 490 to 492
Pharmacological Treatments ATC/SKS
Acetylsalicylic acid B01AC06
Nonsteroidal anti-inflammatory drugs M01A
Vitamin K antagonists B01AA
Digoxin C01AA
Cholesterol-lowering drugs C10A
Systemic glucocorticoids H02AB
TNF inhibitors L04AB01, L04AB02, L04AB04,
and BOHJ18A1-3
Hypertension (a-adrenergic blockers,
nonloop diuretics, vasodilators,
b-blockers, calcium channel
blockers, and renin-angiotensin
system inhibitors)
C02A, C02B, C02C, C02DA,
C02L, C03A, C03B, C03D,
C03E, C03X, C07C, C07D,
C08G, C09BA, C09DA,
C09XA52, C02DB, C02DD,
C02DG, C07, C07F, C08,
C09BB, and C09
ATC indicates anatomical therapeutical chemical; ICD, International Classiﬁcation of
Diseases; SKS, hospital procedure codes; TNF, tumor necrosis factor.
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In line with many autoimmune disease, RA affects women
more often than men with an average sex ratio of 3:1.41 We
therefore also performed a sex-stratiﬁed analysis. Last, to
ensure accurate recording of covariates that could change
over time, we conducted an analysis where the information on
comorbidities and concomitant medication was updated
during follow-up.
Ethics
The Danish Data Protection Agency approved the present
study (ref. 2007-58-0015, int. ref: GEH-2014-018). The
information on study population was encrypted and rendered
anonymous by Statistics Denmark. Retrospective observa-
tional studies do not require ethical approval in Denmark.
Results
Baseline Characteristics
From January 1, 2008 to December 31, 2012, a total of
4 361 869 subjects were found eligible and included in the
study. Individuals with incomplete information on migration
and subjects with previous known HF (n=56 644) were
excluded at the study start. A total of 24 343 subjects were
identiﬁed with RA from 1978 until the study index date. Mean
(SD) disease duration (deﬁned as time between ﬁrst RA
diagnosis and study start) at baseline was 8.1 (5.9) years.
These patients were compared with the reference population
of 4 280 882 individuals without RA. During the study period,
a total of 49 879 and 744 patients with incident HF were
identiﬁed among the reference population and the patients
with RA, respectively. At study baseline, patients with RA were
older than the reference population and had a higher
prevalence of hypertension and diabetes mellitus. Further-
more, there were more females in the RA group, and
compared with the reference population, RA patients had an
increased use of nonsteroidal anti-inﬂammatory drugs, gluco-
corticoids, and acetylsalicylic acid.
A ﬂow chart of the study population is illustrated in Figure,
and baseline characteristics for the study population are
presented in Table 2.
Risk of HF in Patients With RA
The results showed a signiﬁcant association between RA and
incident HF (Table 3). Overall incidence rates of HF were 2.43
(95% CI, 2.41–2.45) and 6.64 (CI 6.18–7.13) per 1000 per-
son-years for the reference population (49 879 cases) and RA
(744 cases), respectively (Table 4).
The time-dependent multivariable Poisson regression
analyses, adjusted for age, sex, and calendar year, showed
increased risk of HF in patients with RA compared with the
reference population with IRR 1.64 (CI, 1.53–1.77). The risk
remained signiﬁcant with IRR 1.30 (CI, 1.17–1.45) in the
fully adjusted analysis when controlling for age, sex,
calendar year, comorbidity, concomitant medications, socioe-
conomic status, alcohol consumption, and smoking history
(Table 3).
Sensitivity Analyses
When the primary study end point was modiﬁed to include a
prescription for loop diuretics and a hospital diagnosis of HF,
the RA-associated increased risk of HF remained statistically
signiﬁcant with IRR 1.30 (CI, 1.26–1.35) in the fully adjusted
analysis. When we excluded all subjects, who were registered
with HF as a secondary diagnosis and only focused on
subjects with HF as a primary diagnosis (27 303 cases), the
association between RA and HF was not considerably altered
(IRR, 1.43 [CI, 1.25–1.65]).
Including treatment with TNF inhibitors in the Poisson
regression models had no signiﬁcant impact on the risk
estimates of HF in RA patients (Table 3). When we adjusted
for concomitant medication and comorbidity that was contin-
uously updated throughout the study period, the results for
RA (IRR, 1.22 [CI, 1.13–1.31]) were also comparable with the
primary analysis. Concerning the impact of sex on risk of HF
in patients with RA, we found a nominally slightly increased
IRR (1.34 [CI, 1.18–1.53]) for females compared with males
(IRR, 1.22 [CI, 1.02–1.47]), but there was no statistical
signiﬁcant difference between the 2 groups.
Figure. Flow chart of selection of study population.
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When we conducted an inception cohort study comprising
the entire Danish population aged ≥18 years followed from
January 1, 2002, a total of 5 291 138 subjects with no history
of RA and HF were eligible for analysis at the study start. Of
these subjects, 14 691 developed new-onset RA and
138 567 were hospitalized for HF during a maximum follow-
up of 11 years. Overall incidence rates of incident HF were
2.58 (CI, 2.56–2.59) and 6.32 (CI, 5.73–6.98) per 1000 per-
son-years for the reference population (38 175 cases) and
patients with RA (392 cases), respectively. Correspondingly,
the fully adjusted IRRs for incident HF were 1.44 (CI, 1.26–
1.65) in patients with RA in this analysis.
Discussion
In the present cohort study of the entire Danish population,
we found an increased risk of incident HF in patients with RA
independent of measured risk factor. Results were supported
by several sensitivity analyses. These ﬁndings suggest the
need for increased awareness regarding the risk of incident
HF in patients with RA.
The increased risk of cardiovascular disease and cardiovas-
cular-related mortality in subjects with RA is well established.2,6
Studies have reported that patients with RA exhibit a doubled risk
of myocardial infarction and 60% increased risk of cardiovascular
mortality compared with the general population.42 An increased
prevalence of traditional risk factors, such as diabetes mellitus,
hypertension, obesity, smoking, and physical inactivity, may
explain, in part, this excess cardiovascular risk in RA.8,11
However, innate as well as adaptive immunemechanisms shared
by RA and cardiovascular disease, namely atherosclerosis, have
emerged as potential contributors to the heightened cardiovas-
cular risk observed in these patients.43,44
HF is a growing public healthcare problem worldwide that
poses a substantial economic burden on national healthcare
Table 2. Baseline Characteristics of the Study Population
Reference
Population
(n=4 280 882)
Rheumatoid
Arthritis
(n=24 343)
Mean (SD) age, y 48.3 (17.8) 60.7 (15.3)
Men, % 2 108 067 (49.2) 6400 (26.3)
Female, % 2 172 815 (50.8) 17 943 (73.7)
Mean (SD) socioeconomic status 2.0 (1.4) 1.9 (1.3)
Alcohol consumption, % 59 614 (1.4) 235 (1.0)
Smoking ever, % 410 101 (9.6) 4353 (17.9)
Comorbidity, %
Arterial vascular disease 30 502 (0.7) 438 (1.9)
Atrial fibrillation 33 668 (0.8) 478 (2.0)
Diabetes mellitus 145 336 (3.4) 1473 (6.1)
Thromboembolism 50 493 (1.2) 659 (2.8)
Hypertension 486 052 (11.4) 5353 (22.0)
Renal disease 8163 (0.2) 116 (0.5)
COPD 25 360 (0.6) 464 (2.0)
Medications, %
Acetylsalicylic acid 316 861 (7.4) 3545 (14.5)
NSAID 528 721 (12.4) 8457 (34.7)
Vitamin K antagonists 52 843 (1.2) 665 (2.7)
Digoxin 28 270 (0.7) 407 (1.7)
Cholesterol-lowering drugs 373 137 (8.7) 3483 (14.3)
Systemic glucocorticoids 79 033 (1.9) 5084 (20.9)
COPD indicates chronic obstructive pulmonary disease.
Table 3. Risk of HF Associated With Rheumatoid Arthritis
Presented as IRRs With 95% CIs
IRR for HF 95% CI P Value
Adjusted for age, sex,
and calendar year
1.64 1.53 to 1.77 <0.001
Adjusted for age, sex,
calendar year,
comorbidity*, medication,
socioeconomic status, alcohol,
and smoking
1.30 1.17 to 1.45 <0.001
Sensitivity analyses
Fully adjusted including
TNF inhibitors
1.29 1.15 to 1.43 <0.001
Fully adjusted with
updated comorbidity
and medications
1.22 1.13 to 1.31 <0.001
Fully adjusted with altered
definition of HF†
1.30 1.26 to 1.35 <0.001
Fully adjusted (IRR of
HF in females)
1.34 1.18 to 1.53 <0.001
Fully adjusted (IRR of
HF in males)
1.22 1.02 to 1.47 <0.003
CI indicates conﬁdence interval; HF, heart failure; IRR, incidence rate ratio; TNF, tumor
necrosis factor.
*Comorbidity included in the analyses: arterial vascular disease, atrial ﬁbrillation,
diabetes mellitus, thromboembolism, hypertension, and renal disease.
†
Altered HF deﬁnition: patients with HF identiﬁed by either a prescription of loop diuretic
or hospital diagnosis.
Table 4. Incidence Rates With 95% CIs Per 1000 Person-
Years of HF and Number of Events
Reference Population Rheumatoid Arthritis
Overall IR (CIs) 2.43 (2.41–2.45) 6.64 (6.18–7.13)
No. of events, n 49 879 744
CI indicates conﬁdence interval; HF, heart failure.
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systems.10,45 In recent years, research has indicated that
persistent systemic inﬂammation may play a pivotal role in
promoting the development and progression of HF through a
vast array of mechanisms, including endothelial dysfunction,
increased arterial stiffness, and adverse myocardial and
vascular remodeling.12,16,18 Notably, proinﬂammatory media-
tors implicated in HF seem to overlap those involved in
various chronic inﬂammatory diseases, such as psoriasis,
inﬂammatory bowel disease, and RA.12,46,47 Moreover, RA has
also been associated with increased arterial stiffness and
endothelial dysfunction that may contribute to development
of HF by increased myocardial afterload and reduced coronary
ﬂow reserve.15,19 Also, RA has been associated with left
ventricular concentric remodeling and systolic and diastolic
left ventricular dysfunction, respectively.13,14,17,21 Even at an
early course of the disease, patients with RA are more likely to
display signiﬁcantly elevated levels of circulating cardiac
biomarkers (eg, troponins, pro-B-type natriuretic peptides)
that are recognized as strong predictors of cardiac diseases,
including HF.48 On these grounds, it is highly conceivable that
a chronic systemic inﬂammatory state in RA may confer an
increased risk of HF that is independent of traditional
cardiovascular risk factors.
Allthough previous studies based on selected populations
have suggested that patients with RA are at increased risk of
developing left ventricular dysfunction and HF, only a single
nationwide study has been conducted and very recently
reported.14,17,20,21,49 Indeed, a register-based Swedish study
found a 22% to 27% increased risk of HF in patients with RA,
with the increased risk being similar for those with ischemic
versus nonischemic HF and strongest for subjects positive for
rheumatoid factor, respectively.20 Notably, RA is a chronic
disease and there is often a signiﬁcant delay from onset of
symptoms to ﬁrst healthcare visit and diagnosis.39,40 To give a
better representation of patients with RA in the general
population, we therefore chose a prevalent study design for
our main analysis, where we did not exclude patients with a
history of RA before the study start. However, we also
performed a sensitivity analysis where we reported IRRs for
new-onset RA with a maximum follow-up of 11 years and
found comparable results. These ﬁndings add importantly to
the evidence provided in the previous studies by demonstrat-
ing a higher risk of incident HF in RA, which appears to be
independent of traditional cardiovascular risk factors.
Besides shared immunoinﬂammatory mechanisms and
over-representation of cardiovascular risk factors, the
increased use of glucocorticoids and TNF inhibitors in patients
with RA may have contributed to our ﬁndings. Glucocorticoids
have multiple adverse effects, including hypertension and salt-
water retention, and limited evidence has suggested that a
long-term use of large doses may accelerate HF.50 On the other
hand, data regarding risk of HF in patients with RA treated with
TNF inhibitors are inconclusive.35–38 In the present study,
however, we adjusted for glucocorticoids and TNF inhibitors in
multivariable regression analyses and found increased risk of
HF in RA patients independent of these agents.
Taken together, the present analysis suggests that patients
with RA have an increased risk of HF that cannot be explained
by established risk factors.
Strengths and Limitations
Notable strengths of the present study include a large number
of unselected participants, adjustment for important con-
founders, the high accuracy of the prospectively recorded
nationwide registries, and information on tax-reported house-
hold income. Also, the Danish government-ﬁnanced health-
care system guarantees care that is free of charge and readily
accessible for all citizens, which minimizes the bias related to
age, sex, comorbidity, and socioeconomic status. In addition,
use of validated measures of exposures and outcomes, as well
as a real-world setting with complete follow-up, add to the
reliability of our results.
Despite these strengths, there are various potentially
important limitations to be acknowledged when interpreting
our ﬁndings. For example, because of the observational nature
of our study, it is not possible to determine causality between
RA and HF. Moreover, the registers lacked information on
important confounding factors, such as echocardiographic
data, circulating lipid and glucose levels, clinical signs of HF,
blood pressure, and body mass index, although we made
some efforts to gauge these effects by use of indirect
measures. Nonetheless, we cannot refute that residual
confounding may have biased our estimates, and the results
should be interpreted accordingly.
Furthermore, because of frequent healthcare contacts,
patients with RA are more likely to be diagnosed with HF at an
early stage, leading to surveillance bias. However, our
sensitivity analysis with use of either a prescription of loop
diuretics and/or a HF diagnosis gave comparable results with
the primary analysis. Also, when analysis was restricted to
cases in which HF was the primary cause of hospitalization,
the results were not affected. Finally, the Danish population is
predominantly of Northern European decent, and generaliz-
ability of our ﬁndings to other ethnicities should be performed
with caution.
Conclusion
The results of the present nationwide study indicate an
increased risk of incident HF in patients with RA. These
ﬁndings add to the existing evidence of RA as a clinically
relevant risk factor for HF and studies of the value of more-
vigilant screening of these patients for HF are warranted.
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Table S1. Procedure and diagnoses codes for smoking history. 
Diagnosis Code (ICD) Excluding 
COPD 490-492 (ICD-8), J42, J44  
Lung cancer 162 (ICD-8), C33, C34  
Nicotine dependence F17  
Tobacco abuse counseling Z716  
Tobacco use Z720 Z720D (Never smoker) 
Toxic effect of tobacco and nicotine T652  
Tobacco smoking Z587 Z587A (Passive smoking) 
Tobacco use, amount VRB0  
   
Treatment/procedure Code (SKS) Excluding 
Treatment with drugs used in nicotine dependence BRHT  
Consultation for smoking cessation (pregnant) BKUA32  
Intervention regarding smoking cessation BQFT01  
Treatment with regards to smoking cessation BRXT  
Education regarding smoking cessation BVDT  
Dialog regarding smoking cessation BQFS01  
Smoker, tried to motivate cessation ZZP0020  
Smoker, not tried to motivate cessation ZZP0021  
Smoker ZZP01A1A  
Smoker, stopping [cessation within last 6 months] ZZP01A1B1  
Former smoker ZZP01A1B2  
COPD rehabilitation ZZ5730  
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Prescriptions Code (ATC) Excluding 
Varenicline N07BA  
Bupropion N06AX12  
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